SCHEMBL1853280

SCHEMBL1853280

CCOC(=O)c1cccc(-c2cccc3nc(CO)cn23)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK3 O43781 1/20 0.48
CCNT1 O60563 1/20 0.48
CCNA2 P20248 1/20 0.48
CDK2 P24941 1/20 0.48
CDK9 P50750 1/20 0.48
CDK5 Q00535 1/20 0.48
DYRK1A Q13627 1/20 0.48
CDK5R1 Q15078 1/20 0.48
DYRK2 Q92630 1/20 0.48
DYRK1B Q9Y463 1/20 0.48
GAA P10253 1/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
MAPK1 P28482 1/20 0.44
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1852801 0.90 GAA (0.46) DYRK3CCNT1CCNA2CDK2CDK9
SCHEMBL1852034 0.82 MAPT (0.43) DYRK3CCNT1CCNA2CDK2CDK9
SCHEMBL3213161 0.75 MEN1 (0.42) DYRK3CCNT1CCNA2CDK2CDK9
SCHEMBL103694 0.75 NUDT1 (0.47) DYRK1ADYRK1BGAARAB9ATP53
SCHEMBL104191 0.74 GAA (0.70) GAACYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL29617015 0.73 TP53 (0.62) SMN1; SMN2NPC1RAB9ATP53POLB
SCHEMBL13247922 0.72 NPSR1 (0.51) SMN1; SMN2NPC1RAB9ATP53POLB
SCHEMBL4193217 0.72 TP53 (0.61) TP53POLBHPGDCYP4F2CYP4A11
SCHEMBL1848831 0.71 DYRK3 (0.48) DYRK3CCNT1CCNA2CDK2CDK9
SCHEMBL11223090 0.70 TP53 (0.59) SMN1; SMN2NPC1RAB9ATP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323978-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-05-25 EP disclosed
WO-2010018874-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 WO disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041891-A1 AMIDE COMPOUND GPR52, GPR132, NR5A2 DYRK3 2807/4885CCNT1 2812/4885CCNA2 1245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.